Skip to main content
Premium Trial:

Request an Annual Quote

FDA OKs Hologic HPV Assays

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Hologic's two assays for human papillomavirus testing, making it the second firm to gain FDA clearance to sell a molecular diagnostic for the condition in the US.

The Bedford, Mass.-based firm received FDA OK for its Cervista HPV HR (high risk) and Cervista HPV 16/18 tests. The HR test is designed to detect the 14 high-risk types of HPV known to cause cervical cancer, while the 16/18 test is the first HPV test approved for genotyping for HPV types 16 and 18, known to be associated with approximately 70% of all cervical cancers in the United States.

Hologic becomes the second company to have regulatory approval to sell an HPV molecular diagnostic test in the US, following Qiagen, which gained the test through its 2007 acquisition of Digene.

Holgic said that the Cervista HPV HR test includes an internal control to verify adequate cellularity for testing, which should reduce the potential for false negative results. The firm also noted that it requires a smaller specimen volume that may minimize inconclusive or indeterminate results, which may lead to fewer patients being called back for repeat testing.

In a research note published this morning, Thomas Weisel Partners analyst Peter Lawson said that he expects the final labeling for the HR test will show comparable performance to Qiagen's test.

"We believe, while competition is increasing, the HPV marketplace is significantly large and underpenetrated, allowing for multiple players to be successful," he wrote. "The US market is around 25 percent penetrated, while penetration in Europe and Asia are in the single digits. The largest driver for the market could occur should the HPV test supplant the Pap as the primary screen, which could occur in smaller European countries in the near future, though widespread adoption is probably years away."

In Friday afternoon trading on the Nasdaq, Hologic's shares were up 11 percent at $11.73, while Qiagen's shares were down 7 percent at $15.08.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.